NO318245B1 - Omeprazol-natriumsalt - Google Patents
Omeprazol-natriumsalt Download PDFInfo
- Publication number
- NO318245B1 NO318245B1 NO19996440A NO996440A NO318245B1 NO 318245 B1 NO318245 B1 NO 318245B1 NO 19996440 A NO19996440 A NO 19996440A NO 996440 A NO996440 A NO 996440A NO 318245 B1 NO318245 B1 NO 318245B1
- Authority
- NO
- Norway
- Prior art keywords
- omeprazole sodium
- omeprazole
- sodium form
- alcohol
- isopropanol
- Prior art date
Links
- RRFCKCAQHRITRG-UHFFFAOYSA-N sodium;5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-3-ide;hydrate Chemical compound O.[Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RRFCKCAQHRITRG-UHFFFAOYSA-N 0.000 title description 92
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 25
- 229960000381 omeprazole Drugs 0.000 claims description 23
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 229940063517 omeprazole sodium Drugs 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000011877 solvent mixture Substances 0.000 claims description 4
- 150000004703 alkoxides Chemical class 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- KNVABRFVZVESIL-UHFFFAOYSA-N sodium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical group [Na+].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C KNVABRFVZVESIL-UHFFFAOYSA-N 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 10
- 159000000000 sodium salts Chemical class 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 238000000634 powder X-ray diffraction Methods 0.000 description 8
- 239000002002 slurry Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000005079 FT-Raman Methods 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003699 antiulcer agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 201000000052 gastrinoma Diseases 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- -1 sesquihydrates Chemical class 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000011549 crystallization solution Substances 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 206010013864 duodenitis Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002325 prokinetic agent Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9702483A SE510643C2 (sv) | 1997-06-27 | 1997-06-27 | Termodynamiskt stabil omeprazol natrium form B |
| PCT/SE1998/001124 WO1999000380A1 (en) | 1997-06-27 | 1998-06-11 | Omeprazole sodium salt |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO996440D0 NO996440D0 (no) | 1999-12-23 |
| NO996440L NO996440L (no) | 2000-02-08 |
| NO318245B1 true NO318245B1 (no) | 2005-02-21 |
Family
ID=20407555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19996440A NO318245B1 (no) | 1997-06-27 | 1999-12-23 | Omeprazol-natriumsalt |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6207188B1 (cs) |
| EP (2) | EP0991641B1 (cs) |
| JP (1) | JP3377218B2 (cs) |
| KR (1) | KR100580987B1 (cs) |
| CN (1) | CN1134432C (cs) |
| AR (1) | AR013350A1 (cs) |
| AT (1) | ATE233756T1 (cs) |
| AU (1) | AU750239B2 (cs) |
| BR (1) | BR9810483A (cs) |
| CA (1) | CA2294614C (cs) |
| CZ (1) | CZ296723B6 (cs) |
| DE (1) | DE69811892T2 (cs) |
| DK (1) | DK0991641T3 (cs) |
| EE (1) | EE03613B1 (cs) |
| EG (1) | EG24224A (cs) |
| ES (1) | ES2191944T3 (cs) |
| HU (1) | HU227976B1 (cs) |
| ID (1) | ID24829A (cs) |
| IL (2) | IL133559A0 (cs) |
| IS (1) | IS1946B (cs) |
| MY (1) | MY127871A (cs) |
| NO (1) | NO318245B1 (cs) |
| NZ (1) | NZ501929A (cs) |
| PL (1) | PL190869B1 (cs) |
| PT (1) | PT991641E (cs) |
| RU (1) | RU2186778C2 (cs) |
| SA (1) | SA98190410B1 (cs) |
| SE (1) | SE510643C2 (cs) |
| SK (1) | SK283958B6 (cs) |
| TR (1) | TR199903270T2 (cs) |
| TW (1) | TW483758B (cs) |
| UA (1) | UA58556C2 (cs) |
| WO (1) | WO1999000380A1 (cs) |
| ZA (1) | ZA985317B (cs) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| ATE355375T1 (de) | 1996-01-04 | 2006-03-15 | Novartis Vaccines & Diagnostic | Bakterioferritin aus helicobacter pylori |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| SE510643C2 (sv) | 1997-06-27 | 1999-06-14 | Astra Ab | Termodynamiskt stabil omeprazol natrium form B |
| SE9900274D0 (sv) * | 1999-01-28 | 1999-01-28 | Astra Ab | New compound |
| IL145220A0 (en) * | 1999-05-20 | 2002-06-30 | Par Pharmaceutical Inc | Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process |
| SE9903831D0 (sv) | 1999-10-22 | 1999-10-22 | Astra Ab | Formulation of substituted benzimidazoles |
| SE0000774D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| US20030212274A1 (en) * | 2000-05-15 | 2003-11-13 | Bakthavathsalan Vijayaraghavan | Novel amorphous form of omeprazole salts |
| US7271182B2 (en) * | 2000-08-04 | 2007-09-18 | Takeda Pharmaceutical Company Limited | Salts of benzimidazole compound and use thereof |
| CA2419067C (en) | 2000-08-18 | 2008-12-23 | Takeda Chemical Industries, Ltd. | Injectable composition comprising benzimidazole compound and strong alkali |
| ES2348710T5 (es) | 2001-06-01 | 2014-02-17 | Pozen, Inc. | Composiciones farmacéuticas para el suministro coordinado de NSAID |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| KR100433735B1 (ko) * | 2001-06-27 | 2004-06-04 | 주식회사 씨트리 | 결정형 ⅰ을 갖는 란소프라졸의 제조방법 |
| SE0102993D0 (sv) | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
| BR0315574A (pt) * | 2002-10-22 | 2005-09-20 | Ranbaxy Lab Ltd | Forma amorfa de esomeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação |
| EP1633736A1 (en) | 2003-05-05 | 2006-03-15 | Ranbaxy Laboratories Limited | Barium salt of benzimidazole derivative |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| FR2871800B1 (fr) * | 2004-06-17 | 2006-08-25 | Sidem Pharma Sa Sa | Sel de sodium monohydrate du s-tenatoprazole et application en therapeutique |
| US8658799B2 (en) * | 2004-06-24 | 2014-02-25 | Astrazeneca Ab | Process for the preparation of crystalline modifications for use in the preparation of esomeperazole sodium salt |
| WO2006073779A1 (en) * | 2004-12-30 | 2006-07-13 | Transform Phamaceuticals, Inc. | Novel omeprazole forms and related methods |
| WO2006131338A2 (en) * | 2005-06-08 | 2006-12-14 | Lek Pharmaceuticals D.D. | Crystalline solvate of omeprazole sodium |
| WO2010029335A1 (en) | 2008-09-09 | 2010-03-18 | Astrazeneca Uk Limited | Method for delivering a pharmaceutical composition to patient in need thereof |
| CN101412710B (zh) * | 2008-12-16 | 2010-04-21 | 海南百那医药发展有限公司 | 一种奥美拉唑钠化合物及其制法 |
| AU2010266026B2 (en) * | 2009-06-25 | 2014-08-07 | Nuvo Pharmaceuticals (Ireland) Designated Activity Company | Method for treating a patient in need of aspirin therapy |
| MX2011013467A (es) | 2009-06-25 | 2012-02-13 | Astrazeneca Ab | Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine). |
| CN102351846B (zh) * | 2011-09-07 | 2012-08-22 | 周晓东 | 一种新的奥美拉唑钠化合物及其药物组合物 |
| CN102319223B (zh) * | 2011-09-21 | 2013-06-19 | 石药集团欧意药业有限公司 | 一种埃索美拉唑冻干制剂及其制备方法 |
| CN102512380B (zh) * | 2011-12-20 | 2013-04-17 | 海南锦瑞制药股份有限公司 | 一种以奥美拉唑钠为活性成分的冻干粉针剂及其制备方法 |
| WO2013101897A2 (en) | 2011-12-28 | 2013-07-04 | Pozen Inc. | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
| CN102827147B (zh) * | 2012-09-13 | 2013-08-07 | 山东罗欣药业股份有限公司 | 一种奥美拉唑钠晶体化合物及含有该晶体化合物的药物组合物 |
| CN102871973A (zh) * | 2012-10-16 | 2013-01-16 | 浙江亚太药业股份有限公司 | 一种奥美拉唑钠冻干制剂及其制备方法 |
| CN103012371B (zh) * | 2013-01-05 | 2014-02-12 | 宁辉 | 奥美拉唑钠结晶化合物、其制备方法及其药物组合物 |
| CN103570687B (zh) * | 2013-11-15 | 2015-01-07 | 悦康药业集团有限公司 | 一种奥美拉唑钠晶体化合物 |
| CN104788426B (zh) * | 2015-04-02 | 2015-12-30 | 天津大学 | 一种奥美拉唑钠半水合物及其制备方法 |
| WO2024075017A1 (en) | 2022-10-04 | 2024-04-11 | Zabirnyk Arsenii | Inhibition of aortic valve calcification |
| CN116041325B (zh) * | 2022-12-09 | 2025-03-07 | 山东北大高科华泰制药有限公司 | 稳定化质子泵抑制剂的方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2719916C2 (de) * | 1977-05-04 | 1987-03-19 | Kali-Chemie Pharma Gmbh, 3000 Hannover | Verfahren zur Herstellung von 2,9-Dioxatricyclo[4,3,1,0↑3↑↑,↑↑7↑]decanen |
| SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| SE8301182D0 (sv) | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| SE9002043D0 (sv) * | 1990-06-07 | 1990-06-07 | Astra Ab | Improved method for synthesis |
| ES2023778A6 (es) * | 1990-12-12 | 1992-02-01 | Genesis Para La Investigacion | Procedimiento para preparar sales alcalinas del omeprazol |
| SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| WO1995032957A1 (en) * | 1994-05-27 | 1995-12-07 | Astra Aktiebolag | Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles |
| DE69535889D1 (de) | 1994-07-08 | 2009-01-02 | Astrazeneca Ab | Aus vielen Einzeleinheiten zusammengesetzte tablettierte Dosisform |
| SE504459C2 (sv) * | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
| CN1042423C (zh) * | 1995-05-25 | 1999-03-10 | 常州市第四制药厂 | 奥美拉唑盐水合物及其制备方法 |
| AU5982198A (en) * | 1997-03-07 | 1998-09-29 | A/S Gea Farmaceutisk Fabrik | Process for the preparation of 2-{{(2-pyridinyl)me thyl}sulfinyl}-1h-benzimidazoles and novel compounds of use for such purpos |
| WO1998040378A1 (en) * | 1997-03-07 | 1998-09-17 | A/S Gea Farmaceutisk Fabrik | Process for the preparation of 2-[[(2-pyridinyl)methyl]sulfinyl]-1h-benzimidazoles and novel compounds of use for such purpose |
| SE510643C2 (sv) | 1997-06-27 | 1999-06-14 | Astra Ab | Termodynamiskt stabil omeprazol natrium form B |
-
1997
- 1997-06-27 SE SE9702483A patent/SE510643C2/sv not_active IP Right Cessation
-
1998
- 1998-06-11 NZ NZ501929A patent/NZ501929A/en not_active IP Right Cessation
- 1998-06-11 TR TR1999/03270T patent/TR199903270T2/xx unknown
- 1998-06-11 CN CNB988066165A patent/CN1134432C/zh not_active Expired - Lifetime
- 1998-06-11 AU AU81353/98A patent/AU750239B2/en not_active Expired
- 1998-06-11 PL PL337735A patent/PL190869B1/pl unknown
- 1998-06-11 EE EEP199900593A patent/EE03613B1/xx not_active IP Right Cessation
- 1998-06-11 RU RU2000100361/04A patent/RU2186778C2/ru active
- 1998-06-11 BR BR9810483-7A patent/BR9810483A/pt not_active Application Discontinuation
- 1998-06-11 JP JP50548499A patent/JP3377218B2/ja not_active Expired - Lifetime
- 1998-06-11 IL IL13355998A patent/IL133559A0/xx active IP Right Grant
- 1998-06-11 ID IDW991685A patent/ID24829A/id unknown
- 1998-06-11 CA CA002294614A patent/CA2294614C/en not_active Expired - Lifetime
- 1998-06-11 CZ CZ0469999A patent/CZ296723B6/cs not_active IP Right Cessation
- 1998-06-11 US US09/101,081 patent/US6207188B1/en not_active Expired - Lifetime
- 1998-06-11 EP EP98931166A patent/EP0991641B1/en not_active Expired - Lifetime
- 1998-06-11 ES ES98931166T patent/ES2191944T3/es not_active Expired - Lifetime
- 1998-06-11 WO PCT/SE1998/001124 patent/WO1999000380A1/en active IP Right Grant
- 1998-06-11 KR KR1019997012236A patent/KR100580987B1/ko not_active Expired - Fee Related
- 1998-06-11 HU HU0003017A patent/HU227976B1/hu not_active IP Right Cessation
- 1998-06-11 EP EP01128973A patent/EP1186602A3/en not_active Withdrawn
- 1998-06-11 AT AT98931166T patent/ATE233756T1/de active
- 1998-06-11 DK DK98931166T patent/DK0991641T3/da active
- 1998-06-11 DE DE69811892T patent/DE69811892T2/de not_active Expired - Lifetime
- 1998-06-11 SK SK1729-99A patent/SK283958B6/sk not_active IP Right Cessation
- 1998-06-11 PT PT98931166T patent/PT991641E/pt unknown
- 1998-06-15 TW TW087109498A patent/TW483758B/zh not_active IP Right Cessation
- 1998-06-16 AR ARP980102857A patent/AR013350A1/es active IP Right Grant
- 1998-06-18 ZA ZA985317A patent/ZA985317B/xx unknown
- 1998-06-24 EG EG74298A patent/EG24224A/xx active
- 1998-06-26 MY MYPI98002907A patent/MY127871A/en unknown
- 1998-08-19 SA SA98190410A patent/SA98190410B1/ar unknown
- 1998-11-06 UA UA99126959A patent/UA58556C2/uk unknown
-
1999
- 1999-12-16 IL IL133559A patent/IL133559A/en not_active IP Right Cessation
- 1999-12-21 IS IS5314A patent/IS1946B/is unknown
- 1999-12-23 NO NO19996440A patent/NO318245B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO318245B1 (no) | Omeprazol-natriumsalt | |
| AU722839B2 (en) | Novel form of S-omeprazole | |
| US6262085B1 (en) | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same | |
| NO320014B1 (no) | Ny krystallinsk form for omeprazol, fremgangsmate for fremstilling derav, omeprazolsammensetning, farmasoytisk formulering samt anvendelse av omeprazolformen. | |
| NO317191B1 (no) | S-omeprazol i noytral form, fremgangsmate for fremstilling derav, farmasoytisk preparat inneholdende en slik form, og anvendelse derav | |
| NO319719B1 (no) | Kaliumsalt av (S)-omeprazol | |
| US8658799B2 (en) | Process for the preparation of crystalline modifications for use in the preparation of esomeperazole sodium salt | |
| WO2004072061A1 (en) | Method of stabilizing lansoprazole | |
| US20060122233A1 (en) | Rabeprazole calcium | |
| MXPA99011674A (en) | Omeprazole sodium salt | |
| HK1026699B (en) | Crystalline form of omeprazole sodium salt | |
| US20060094762A1 (en) | Magnesium salt of imidazole derivative | |
| CZ296154B6 (cs) | Trihydrát horecnaté soli S-omeprazolu, zpusob jeho prípravy a farmaceutický prostredek s jeho obsahem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |